Anti-tumor Activity of Toll-Like Receptor 7 Agonists

Toll-like receptors (TLRs) are a class of pattern recognition receptors that play a bridging role in innate immunity and adaptive immunity. The activated TLRs not only induce inflammatory responses, but also elicit the development of antigen specific immunity. TLR7, a member of TLR family, is an intracellular receptor expressed on the membrane of endosomes. TLR7 can be triggered not only by ssRNA during viral infections, but also by immune modifiers that share a similar structure to nucleosides. Its powerful immune stimulatory action can be potentially used in the anti-tumor therapy. This article reviewed the anti-tumor activity and mechanism of TLR7 agonists that are frequently applied in preclinical and clinical investigations, and mainly focused on small synthetic molecules, including imiquimod, resiquimod, gardiquimod, and 852A, etc.

• Publication year

  2017

• Venue

  Frontiers in Pharmacology

• Publication date

  2017-05-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3389/fphar.2017.00304PMID 28620298PMCID 5450331
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Local Administration

  2018cited by this paper
• Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial

  2017cited by this paper
• TRAF6 is a critical factor in fish immune response to virus infection

  2017influential reference
• Beneficial effect of low-level laser therapy in acute lung injury after i-I/R is dependent on the secretion of IL-10 and independent of the TLR/MyD88 signaling

  2017cited by this paper
• The TLR3 Agonist Inhibit Drug Efflux and Sequentially Consolidates Low-Dose Cisplatin-Based Chemoimmunotherapy while Reducing Side Effects

  2017cited by this paper
• Cloning and functional characterization of IRAK4 in large yellow croaker (Larimichthys crocea) that associates with MyD88 but impairs NF‐&kgr;B activation

  2017cited by this paper
• TLR7 Structure: Cut in Z-Loop.

  2016cited by this paper
• Imiquimod activates p53-dependent apoptosis in a human basal cell carcinoma cell line.

  2016cited by this paper
• Inhibition of IL-1R1/MyD88 signalling promotes mesenchymal stem cell-driven tissue regeneration

  2016cited by this paper
• A Standardized Chemically Modified Curcuma longa Extract Modulates IRAK-MAPK Signaling in Inflammation and Potentiates Cytotoxicity

  2016cited by this paper
• Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy

  2016cited by this paper
• TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells

  2016cited by this paper
• Toll-like receptors signaling: A complex network for NF-κB activation in B-cell lymphoid malignancies.

  2016cited by this paper
• A Multifaceted Role for Myd88-Dependent Signaling in Progression of Murine Mammary Carcinoma

  2016cited by this paper
• Antitumor activity of a novel small molecule TLR7 agonist via immune response induction and tumor microenvironment modulation.

  2016cited by this paper
• Poly(I:C) potentiates Bacillus Calmette–Guérin immunotherapy for bladder cancer

  2016cited by this paper
• Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases

  2016cited by this paper
• A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice

  2016cited by this paper
• A video-based educational pilot for basal cell carcinoma (BCC) treatment: A randomized controlled trial.

  2016cited by this paper
• Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine

  2016cited by this paper
• Activation of Toll-like receptor 7 inhibits the proliferation and migration, and induces the apoptosis of pancreatic cancer cells.

  2015cited by this paper
• Inhibition of indoleamine 2,3‐dioxygenase activity enhances the anti‐tumour effects of a Toll‐like receptor 7 agonist in an established cancer model

  2015cited by this paper
• Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial

  2015cited by this paper
• Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma

  2015cited by this paper
• TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice

  2015cited by this paper
• Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment

  2015cited by this paper
• Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects.

  2015cited by this paper
• Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice

  2015cited by this paper
• Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma.

  2015cited by this paper
• Toll-like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model.

  2015cited by this paper
• Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma

  2015cited by this paper
• The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma.

  2014cited by this paper
• Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

  2014cited by this paper
• Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation

  2014cited by this paper
• The role of TLR8 signaling in Acute Myeloid Leukemia Differentiation

  2014cited by this paper
• A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma

  2014cited by this paper
• A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models

  2014cited by this paper
• Pharmacokinetic and Pharmacodynamic Properties of GS-9620, a Novel Toll-Like Receptor 7 Agonist, Demonstrate Interferon-Stimulated Gene Induction without Detectable Serum Interferon at Low Oral Doses

  2014cited by this paper
• Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors

  2014cited by this paper
• Phosphorothioate-modified CpG oligodeoxynucleotide (CpG ODN) induces apoptosis of human hepatocellular carcinoma cells independent of TLR9

  2014cited by this paper
• The TLR7 agonist induces tumor regression both by promoting CD4+T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells

  2014cited by this paper
• A Flagellin-Derived Toll-Like Receptor 5 Agonist Stimulates Cytotoxic Lymphocyte-Mediated Tumor Immunity

  2014cited by this paper
• Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARβ and tumor regression

  2013cited by this paper
• GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.

  2013cited by this paper
• Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.

  2013cited by this paper
• The history of Toll-like receptors — redefining innate immunity

  2013cited by this paper
• Poly(I:C) exhibits an anti-cancer effect in human gastric adenocarcinoma cells which is dependent on RLRs.

  2013cited by this paper
• In vitro and in vivo growth inhibition of prostate cancer by the small molecule imiquimod.

  2013cited by this paper
• IL-27 Enhances the Expression of TRAIL and TLR3 in Human Melanomas and Inhibits Their Tumor Growth in Cooperation with a TLR3 Agonist Poly(I:C) Partly in a TRAIL-Dependent Manner

  2013cited by this paper
• Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells

  2013cited by this paper
• Inhibitory effect of dsRNA TLR3 agonist in a rat hepatocellular carcinoma model.

  2013cited by this paper
• Trial watch

  2013cited by this paper
• Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility.

  2013cited by this paper
• Intratracheal and oral administration of SM‐276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer

  2013cited by this paper
• Induction of pro-inflammatory cytokine production in thymocytes by the immune response modifiers Imiquimod and Gardiquimod™.

  2013cited by this paper
• Pharmacokinetics of Daily Self‐Application of Imiquimod 3.75% Cream in Adult Patients With External Anogenital Warts

  2012cited by this paper
• Synergy of Topical Toll-like Receptor 7 Agonist with Radiation and Low-Dose Cyclophosphamide in a Mouse Model of Cutaneous Breast Cancer

  2012cited by this paper
• Toll-like receptor 5 agonist inhibition of growth of A549 lung cancer cells in vivo in a Myd88 dependent manner.

  2012cited by this paper
• Toll-like receptor 7 agonist, imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis.

  2012cited by this paper
• TLR3 dsRNA agonist inhibits growth and invasion of HepG2.2.15 HCC cells.

  2012cited by this paper
• Toll-like Receptor 5 Agonist Inhibition of Growth of A 549 Lung Cancer Cells in Vivo in a Myd 88 Dependent Manner

  2012cited by this paper
• Prolonged subcutaneous administration of 852A, a novel systemic toll‐like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies

  2012cited by this paper
• Trial watch

  2012cited by this paper
• Trial Watch

  2012cited by this paper
• Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer

  2012cited by this paper
• Critical Reviews in Oral Biology & Medicine: TLR-signaling Networks: An Integration of Adaptor Molecules, Kinases, and Cross-talk

  2011cited by this paper
• Toll-like receptor 7 stimulation promotes autoimmune diabetes in the NOD mouse

  2011cited by this paper
• TLR1/TLR2 Agonist Induces Tumor Regression by Reciprocal Modulation of Effector and Regulatory T Cells

  2011cited by this paper
• Immunomodulation by imiquimod in patients with high-risk primary melanoma

  2011cited by this paper
• Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment

  2011cited by this paper
• TLR-signaling Networks

  2011cited by this paper
• Intratumoral Administration of TLR4 Agonist Absorbed into a Cellular Vector Improves Antitumor Responses

  2011cited by this paper
• Triggering of Toll-like Receptor-2 in Mouse Myelomonocytic Leukaemia Cells WEHI-3B Leads to the Suppression of Apoptosis and Promotes Tumor Progression in Vivo

  2011cited by this paper
• Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers

  2011cited by this paper
• In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.

  2010cited by this paper
• The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice

  2010cited by this paper
• DAMPening Inflammation by Modulating TLR Signalling

  2010cited by this paper
• Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance.

  2010cited by this paper
• Treatment Failure of a TLR-7 Agonist Occurs Due to Self-Regulation of Acute Inflammation and Can Be Overcome by IL-10 Blockade

  2010cited by this paper
• Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.

  2010cited by this paper
• Intravesical Toll‐like receptor 7 agonist R‐837: Optimization of its formulation in an orthotopic mouse model of bladder cancer

  2010cited by this paper
• A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine.

  2010cited by this paper
• Targeting Toll-like receptors: emerging therapeutics?

  2010cited by this paper
• Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist

  2010cited by this paper
• The TAK1-TRAF6 signalling pathway.

  2010cited by this paper
• Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers

  2010cited by this paper
• A Critical Role for Mast Cells and Mast Cell-Derived IL-6 in TLR2-Mediated Inhibition of Tumor Growth

  2010cited by this paper
• A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia

  2010cited by this paper
• Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha.

  2010cited by this paper
• The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells

  2009cited by this paper
• NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model

  2009cited by this paper
• Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin.

  2009cited by this paper
• Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

  2009cited by this paper
• TLR9 Signaling Promotes Tumor Progression of Human Lung Cancer Cell In Vivo

  2009cited by this paper
• Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy1

  2009cited by this paper
• Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates

  2009cited by this paper
• Reversal of Human Papillomavirus-Specific T Cell Immune Suppression through TLR Agonist Treatment of Langerhans Cells Exposed to Human Papillomavirus Type 161

  2009cited by this paper
• Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9

  2009cited by this paper
• Regression of Established AB1 Murine Mesothelioma Induced by Peritumoral Injections of CpG Oligodeoxynucleotide Either Alone or in Combination with Poly(I:C) and CD40 Ligand Plasmid DNA

  2009cited by this paper
• An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models

  2009cited by this paper

• The Role of Unmethylated 5′-C-Phosphate-G-3′ (CpG) Motifs in Mitochondrial and Bacterial DNA in the Pathogenesis of Alzheimer’s Disease

  2026cites this paper
• Hydrogel-based delivery of cytokines in cancer immunotherapy: Latest evidence and therapeutic outcomes.

  2026cites this paper
• Toll-like Receptor 7/8 Agonists Exert Antitumor Effect in a Mouse Melanoma Model

  2026cites this paper
• Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer

  2025cites this paper
• Identification of new triazoloquinoxaline amine derivatives with potent modulatory effects against Toll-like receptor 7 through pharmacophore-based virtual screening and molecular docking approaches

  2025cites this paper
• Methionine enkephalin upregulates toll-like receptors in macrophages to suppress severe fever with thrombocytopenia syndrome virus infection

  2025cites this paper
• A cascade-regulated nanoadjuvant for antigen oxidation and capture to potentiate in-situ cancer vaccination.

  2025cites this paper
• High‐Integrity Nanoformulation of Resiquimod (R848) for Dual Autophagy Activation and PD‐L1 Modulation in Triple‐Negative Breast Cancer

  2025cites this paper
• Micellar formulation provides potent and tolerable TLR7 agonist treatment for anti-cancer immunotherapy.

  2025cites this paper
• High-integrity nanoemulsions formulation of resiquimod (R848) enhances stability and delivery for triple negative breast cancer immunotherapy

  2025cites this paper
• Construction and expression of multi-stage antigen fusion protein RPC4 vaccine for Mycobacterium tuberculosis and its immunogenicity analysis in combination with adjuvant DIMQ.

  2025cites this paper
• Multidimensional applications of prussian blue-based nanoparticles in cancer immunotherapy

  2025cites this paper
• Lignin-chitosan-based biocomposite film for the localized delivery of TLR7 agonist imiquimod

  2024cites this paper
• Oral cancer immunology: state of the art and future perspectives.

  2024cites this paper
• The novel selective TLR7 agonist GY101 suppresses colon cancer growth by stimulating immune cells.

  2024cites this paper
• Imiquimod for the treatment of morphea: a systematic review

  2024cites this paper
• Multifunctional mesoporous polydopamine nanoplatforms for synergistic photothermal-chemotherapy and enhanced immunotherapy in breast cancer treatment.

  2024cites this paper
• An Exploratory Study of Early Immune Response Markers for Pembrolizumab in Urothelial Tract Cancer

  2024cites this paper
• Targeting the lung tumour stroma: harnessing nanoparticles for effective therapeutic interventions

  2024cites this paper
• Targeting Innate Immunity in Glioma Therapy

  2024cites this paper
• A Dual-Payload Antibody–Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer

  2024cites this paper
• Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology.

  2024cites this paper
• Small molecule innate immune modulators in cancer therapy

  2024cites this paper
• An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses

  2024cites this paper
• A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

  2024cites this paper
• Radiotherapy Combined with Intralesional Immunostimulatory Agents for Soft Tissue Sarcomas.

  2024cites this paper
• Combined Cancer Immunotheranostic Nanomedicines: Delivery Technologies and Therapeutic Outcomes

  2023cites this paper
• TLR7 promotes smoke-induced experimental lung damage through the activity of mast cell tryptase

  2023cites this paper
• Molecular markers that predict response to combined radiotherapy and immunotherapy in patients with lung adenocarcinoma: a bioinformatics analysis

  2023cites this paper
• Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy

  2023cites this paper
• Self-sufficient nanoparticles with dual-enzyme activity trigger radical storms and activate cascade-amplified antitumor immunologic responses

  2023cites this paper
• Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives

  2023cites this paper
• Subverted macrophages in the triple-negative breast cancer ecosystem.

  2023cites this paper
• Engineering of a graphene oxide-based two-dimensional platform for immune activation and modulation

  2023cites this paper
• Cancer Cell Membrane-Coated Nanoparticle Co-loaded with Photosensitizer and Toll-like Receptor 7 Agonist for the Enhancement of Combined Tumor Immunotherapy.

  2023cites this paper
• Adjuvant physiochemistry and advanced nanotechnology for vaccine development.

  2023cites this paper
• Imidazoquinolines with improved pharmacokinetic properties induce a high IFNα to TNFα ratio in vitro and in vivo

  2023cites this paper
• 5-FU mediated depletion of myeloid suppressor cells enhances T-cell infiltration and anti-tumor response in immunotherapy-resistant lung tumor.

  2023cites this paper
• Poly(Ethylene Glycol)-Poly(Lactic Acid) TLR7 Agonist as a Novel HBsAg Immune Response Stimulant

  2023cites this paper
• Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer

  2023cites this paper
• Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer

  2023cites this paper
• Ionic Liquid-Based Transcutaneous Peptide Antitumor Vaccine: Therapeutic Effect in a Mouse Tumor Model

  2023cites this paper
• Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors

  2023cites this paper
• Tumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy

  2022cites this paper
• Local immunotherapy of cancer and metastasis

  2022cites this paper
• Conjugate of ibrutinib with a TLR7 agonist suppresses melanoma progression and enhances antitumor immunity

  2022cites this paper
• Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective

  2022cites this paper
• Solid Lipid Nanoparticles-Based Drug and Gene Delivery to Macrophages

  2022cites this paper
• Tumor-Associated Macrophages: Therapeutic Targets of Cancer

  2022cites this paper
• Polymeric Nanoparticles-Based Drug and Gene Delivery to Macrophages

  2022cites this paper
• A Novel Multiepitope Vaccine Against Bladder Cancer Based on CTL and HTL Epitopes for Induction of Strong Immune Using Immunoinformatics Approaches

  2022cites this paper
• Targeting toll-like receptors on T cells as a therapeutic strategy against tumors.

  2022cites this paper
• The miR-145-MMP1 axis is a critical regulator for imiquimod-induced cancer stemness and chemoresistance.

  2022cites this paper
• Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands

  2022cites this paper
• Glyco-Nanoadjuvants: Impact of Linker Length for Conjugating a Synthetic Small-Molecule TLR7 Ligand to Glyco-Nanoparticles on Immunostimulatory Effects.

  2022cites this paper
• Therapeutic Effect of mRNA SARS-CoV-2 Vaccine on Melanoma Skin Metastases

  2022cites this paper
• Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity

  2022cites this paper
• Phosphoinositide 3-kinase/Akt and its related signaling pathways in the regulation of tumor-associated macrophages polarization

  2022cites this paper
• Combination of Radiofrequency Ablation With Resiquimod to Treat Hepatocellular Carcinoma Via Inflammation of Tumor Immune Microenvironment and Suppression of Angiogenesis

  2022cites this paper
• The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy

  2022cites this paper
• Ivermectin Enhanced Antitumor Activity of Resiquimod in a Co-loaded Squalene Emulsion.

  2022cites this paper
• Breaking the niche: multidimensional nanotherapeutics for tumor microenvironment modulation

  2022cites this paper
• The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview

  2022cites this paper
• Adipocytes Encapsulating Telratolimod Recruit and Polarize Tumor‐Associated Macrophages for Cancer Immunotherapy

  2022cites this paper
• Metabolic guidance and stress in tumors modulate antigen-presenting cells

  2022cites this paper
• Tumor Cell-Surface Binding of Immune Stimulating Polymeric Glyco-Adjuvant via Cysteine-Reactive Pyridyl Disulfide Promotes Antitumor Immunity

  2022cites this paper
• Endothelial Cell–Derived Let-7c-Induced TLR7 Activation on Smooth Muscle Cell Mediate Vascular Wall Remodeling in Moyamoya Disease

  2022cites this paper
• Preclinical Characterization and Phase 1 Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies.

  2022cites this paper
• Application of dendritic cells in tumor immunotherapy and progress in the mechanism of anti-tumor effect of Astragalus polysaccharide (APS) modulating dendritic cells: a review.

  2022cites this paper
• A translational strategy employing physiologically based modelling to predict the pharmacological active dose of RO7119929, an oral prodrug of a targeted cancer immunotherapy TLR7 agonist

  2022cites this paper
• Evaluation of a Radio-IMmunoStimulant (RIMS) in a Syngeneic Model of Murine Prostate Cancer and ImmunoPET Analysis of T-cell Distribution.

  2022cites this paper
• TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism

  2022cites this paper
• Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists

  2022cites this paper
• Photothermal immunotherapy of melanoma using TLR-7 agonist laden tobacco mosaic virus with polydopamine coat.

  2022cites this paper
• Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors

  2021cites this paper
• Immune-keratinocyte crosstalk in healthy and cancerous epidermis

  2021cites this paper
• Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment

  2021cites this paper
• Systemic Immunotherapy with Micellar Resiquimod–Polymer Conjugates Triggers a Robust Antitumor Response in a Breast Cancer Model

  2021cites this paper
• Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors

  2021cites this paper
• Inhibitory Effect of Immunologically Activated Mesenchymal Stem Cells on Lung Cancer Cell Growth and Metastasis

  2021cites this paper
• ICAM-1 orchestrates the abscopal effect of tumor radiotherapy

  2021cites this paper
• In vitro evidence suggesting that the toll-like receptor 7 and 8 agonist resiquimod (R-848) unlikely affects drug levels of co-administered compounds.

  2021cites this paper
• Nucleic Acid Nanoparticles (NANPs) as Molecular Tools to Direct Desirable and Avoid Undesirable Immunological Effects.

  2021cites this paper
• Inhibition of TLR7 and TLR9 Reduces Human Cholangiocarcinoma Cell Proliferation and Tumor Development

  2021cites this paper
• Glyco-Nanoadjuvants: Sugar Structures on Carriers of a Small Molecule TLR7 Ligand Affect Their Immunostimulatory Activities.

  2021cites this paper
• Induction of OCT2 contributes to regulate the gene expression program in human neutrophils activated via TLR8.

  2021cites this paper
• Molecular and Macroscopic Therapeutic Systems for Cytokine‐Based Cancer Immunotherapy

  2021cites this paper
• A dual macrophage polarizer conjugate for synergistic melanoma therapy.

  2021cites this paper
• Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants

  2021influential citation
• Magnetic Nanostructures as Emerging Therapeutic Tools to Boost Anti-Tumour Immunity

  2021cites this paper
• Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications

  2021cites this paper
• Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy

  2021cites this paper
• Toll-Like Receptors: General Molecular and Structural Biology

  2021cites this paper
• The Role of Toll-Like Receptor (TLR) Polymorphisms in Urinary Bladder Cancer

  2021cites this paper
• Sequence-specific extracellular microRNAs activate TLR7 and induce cytokine secretion and leukocyte migration

  2021cites this paper
• Monocyte-dependent co-stimulation of cytokine induction in human γδ T cells by TLR8 RNA ligands

  2021cites this paper
• Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles.

  2021cites this paper
• Recombinant single-cycle influenza virus as a new tool to augment antitumour immunity with immune checkpoint inhibitors

  2021cites this paper
• Overcoming Chemoimmunotherapy‐Induced Immunosuppression by Assemblable and Depot Forming Immune Modulating Nanosuspension

  2021cites this paper
• Short Review on Advances in Hydrogel-Based Drug Delivery Strategies for Cancer Immunotherapy

  2021cites this paper